Sonoma Pharmaceuticals (SNOA) Income from Continuing Operations (2010 - 2025)

Sonoma Pharmaceuticals' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 819000.0 for Q4 2025.

• In Q4 2025, Income from Continuing Operations rose 11.75% year-over-year to 819000.0; the TTM figure through Dec 2025 stood at 3370000.0 (up 10.09% YoY), while the FY2025 annual figure was 3457000.0, up 28.5% from the prior year.
• Income from Continuing Operations was 819000.0 for Q4 2025 at Sonoma Pharmaceuticals, down from 534000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 100000.0 in Q3 2021 to a low of 3753000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 1272850.0 across 5 years, with a median of 1042000.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 917.0% in 2022, then jumped 65.15% in 2023.
• A 5-year view of Income from Continuing Operations shows it stood at 944000.0 in 2021, then slumped by 105.4% to 1939000.0 in 2022, then jumped by 55.34% to 866000.0 in 2023, then decreased by 7.16% to 928000.0 in 2024, then increased by 11.75% to 819000.0 in 2025.
• The last three Income from Continuing Operations figures came in at 819000.0 (Q4 2025), 534000.0 (Q3 2025), and 1241000.0 (Q2 2025), per Business Quant data.